In the BioHarmony Drug Report Database

"Preview" Icon

Latanoprostene bunod

Vyzulta (latanoprostene bunod) is a small molecule pharmaceutical. Latanoprostene bunod was first approved as Vyzulta on 2017-11-02. It is known to target prostaglandin F2-alpha receptor. Vyzulta’s patent is valid until 2025-10-03 (FDA).

 

Trade Name

 

Vyzulta
 

Common Name

 

latanoprostene bunod
 

ChEMBL ID

 

CHEMBL2364612
 

Indication

 

 

Drug Class

 

Nitrogen oxide (eg., nitrxyl and nitric oxide) donors; prostaglandins

Image (chem structure or protein)

Latanoprostene bunod structure rendering